Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer is the 10 th most commonly occurring malignancy worldwide with a 75% of 5-
year survival rate, while it ranks 13 th among the deaths occurring due to cancer. The …

Simple Summary The study discusses the potential of targeting transcription factors (TFs) for
cancer therapy and provide a systematic classification of various types of TFs involved in the …

Bladder cancer is the ninth most common cancer worldwide with a striking sex-based
difference in incidence. Emerging evidence indicates that the androgen receptor (AR) might …

Background Solanum nigrum L. decoction has been used as a folklore medicine in China to
prevent the postoperative recurrence of bladder cancer (BC). However, there are no …

Objective Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in
multiple malignancies and associated with patients' prognosis, but its role in bladder cancer …

Melanoma antigen gene (MAGE)-A6 and MAGE-A11 are two of the most cancer-testis
antigens overexpressed in various types of cancers. However, the clinical and prognosis …

Sex-related differences in bladder cancer incidence and progression infer a role for sex
hormones and their cognate receptors in this disease. In part due to the oncogenic role of …

The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and
continues to dominate the treatment landscape for advanced prostate cancer, where nearly …

Bladder cancer (urothelial carcinoma) is one of the most frequently diagnosed neoplasms,
with an estimated half a million new cases and 200,000 deaths per year worldwide. This …